RedHill Biopharma

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases

[RedHill Biopharma @RedHillBio]

2 leading microbiology centers confirm #RDHL’s #RHB204’s MAP-killing capability & comparability to #RHB104 in vitro, in both long-term intracellular culture & spot/phage assays, supports RHB-204’s development in MAP-related #Crohnsdisease (#CD). $RDHL PR: https://t.co/s0nc9oKVoY

[RedHill Biopharma @RedHillBio]

$2.9 million grant from @NIH’s @theNCI awarded to @UofOklahoma for clinical development of #RDHL’s #opaganib and CAR T-cell combination for treatment of ultra-high-risk #multiplemyeloma. Full RDHL PR: https://t.co/gTixEj5vhw

[RedHill Biopharma @RedHillBio]

$RDHL 1H26 Highlights: Strategic portfolio reset - $12M acquisition of Rebyota and Clenpiq rights ($37.5 million 2025 net sales) funded by $18M Talicia sale. Stronger, improved liquidity, growth opportunities & potential for new products. #RDHL PR: https://t.co/9HRQLYqAO5

[RedHill Biopharma @RedHillBio]

https://t.co/wRG9I1JuzJ

[RedHill Biopharma @RedHillBio]

$RDHL transformational acquisition of commercialization rights to @ferring’s Rebyota® + Clenpiq®, $37.5m 2025 sales, for $12m upfront payment, fully funded by the $18m Talicia divestment - creates stronger liquidity position & growth catalyst. #RDHL PR: https://t.co/UaeMILED88

[RedHill Biopharma @RedHillBio]

$RDHL divests #Talicia to Apotex ($APTX) for $18m + up to $35m in potential add on payments to fuel strategic growth opportunities - execution of a major step on a strategic roadmap to fundamentally reposition #RDHL's commercial business. Full PR:https://t.co/AVcK2XNQOT

[RedHill Biopharma @RedHill_DE]

#RDHL updates on #opaganib #Bundibugyo #ebola development as cases and deaths rise significantly. Finalization of development next steps and potential partnership discussions are ongoing, including with the AMA, #Uganda MoH, #DRC & @MbararaUST. $RDHL PR: https://t.co/LC8hNvi5T2

[RedHill Biopharma @RedHillBio]

$RDHL announces closing of up to $19.4M private placement ($6M upfront with up to $13.4M of potential proceeds) expected to strenghten liquidity & support potential transformative revenue generating acquisitions. #RDHL PR:https://t.co/CASVQw2nqa

[RedHill Biopharma @RedHillBio]

$RDHL announces up to $19.4 million private placement - $6 million upfront with up to approximately $13.4 million of potential aggregate proceeds to support a potential strategic acquisition. #RDHL PR: https://t.co/K0C67SmKCk

[RedHill Biopharma @RedHillBio]

#RDHL’s #opaganib receives @FDA rare pediatric disease designation for neuroblastoma, with potential for #PriorityReviewVoucher. Adds to prior #orphandrugdesignation. $RDHL PR: https://t.co/LYWQxhBAmU

[RedHill Biopharma @RedHillBio]

$RDHL has commenced recognition and enforcement proceedings in #Korea for the $11 million #NewYork #SupremeCourt final judgment in favor of #RDHL against #Kukbo. Press release: https://t.co/M63d67g3Ik

[RedHill Biopharma @RedHillBio]

#RDHL advancing #opaganib options for #Ebola biodefense platforms, incl. @WHO’s SOLIDARITY CORE clinical trial platform & pharma collaborations, amid rapidly evolving #Bundibugyo #EVD outbreak, which has no approved medications or vaccines. $RDHL PR: https://t.co/szELNeszK0

[RedHill Biopharma @RedHillBio]

#RDHL’s RHB-204 comparable MAP killing efficacy to RHB-104, with lower doses. Key step in RHB-204’s FDA-guided path to potential groundbreaking MAP-related approach to #Crohns. Multiple FDA designations, possible PRV and regulatory exclusivities. $RDHL PR: https://t.co/S3ynsaSoM3

[RedHill Biopharma @RedHillBio]

$RDHL FY2025: Tenacity, transactions & traction - transformed #Talicia business with $4M Cumberland $CPIX deal, RHB-102 deal worth up to $60M with @Hyloris, positive equity at end 2025 & R&D advances in #Crohn’s, #oncology & #GLP1 GI effects. #RDHL PR: https://t.co/htoUvXJnYi

[RedHill Biopharma @RedHillBio]

New preclinical data presented @AACR #AACR2026 annual meeting shows positive effects of #RDHL’s #opaganib as potential add-on therapy in models of #neuroblastoma (#NB) and triple-negative #breastcancer (#TNBC). $RDHL PR: https://t.co/gXFWAHsdiO

[RedHill Biopharma @RedHillBio]

#RDHL announces the start of joint U.S. commercialization of #Talicia with Cumberland ($CPIX), with full sales and operational launch commencing to support accelerated market penetration and expanded reach. $RDHL PR: https://t.co/gXj7Km2500

[RedHill Biopharma @RedHillBio]

#RDHL progress for #RHB-102 (#Bekinda®) in multiple GI indications, including development via FDA 505(b)(2) route, as a once-daily pill for #GLP1 GI side effects – no. 1 reason patients stop therapy, limiting $billion GLP-1 market growth. $RDHL PR: https://t.co/2oFRVPOHAG

[RedHill Biopharma @RedHillBio]

#RDHL’s opaganib plus venetoclax halves number of venetoclax-resistant #CLL #cancer cells in vivo compared to control – potential as add-on therapy to $2.5B blockbuster in emerging venetoclax-resistant CLL therapeutic challenge. $RDHL PR: https://t.co/3o1HFkcRLi @GamberaleRomina

[RedHill Biopharma @RedHillBio]

$RDHL successfully regains compliance with the @Nasdaq stockholders’ equity requirement. #RDHL PR: https://t.co/XFw3u4kUw9

[RedHill Biopharma @RedHillBio]

$RDHL’s $10.5 million New York Supreme Court judgment win now final for enforcement. No further appeal permissible. 9% annual statutory interest continues to accrue on award. #RDHL PR: https://t.co/zy3jqBJoJG